4.7 Review

Encapsulation of NSAIDs for inflammation management: Overview, progress, challenges and prospects

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 515, Issue 1-2, Pages 757-773

Publisher

ELSEVIER
DOI: 10.1016/j.ijpharm.2016.11.002

Keywords

Non-steroidal anti-inflammatory drugs; Encapsulation; Carriers; Liposomes; Particles; Solid lipid nanoparticles; In vivo

Funding

  1. French embassy
  2. Afghanistan higher education ministry

Ask authors/readers for more resources

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed drugs. Debilitating diseases such as rheumatoid arthritis and osteoarthritis are commonly managed by NSAIDs. However, NSAIDs pharmacological mechanism is often associated with the presence of gastrointestinal side effects. NSAIDs encapsulation is performed in order to overcome some of the drawbacks linked to their clinical use. To fulfill this purpose, various vectors like polymer-based nanoparticles, liposomes and solid lipid nanoparticles have been proposed. Such vehicles could have advantages but some limitations as well. This manuscript highlights current NSAIDs encapsulation approaches based on either preformed polymers or lipids. Moreover, properties of the prepared carriers and their applications are also discussed. Many factors are taken into account for selecting carrier type and encapsulation method. It was concluded that different vehicles and preparation methods have been employed for NSAIDs encapsulation. Mostly, vehicles sizes ranged within the nanoscale. Main advantages that have been confirmed by in vitro and in vivo studies include promoted stability, sustained release and bioavailability enhancement. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available